Treating Chronic Insomnia in Breast Cancer Patients
Chronic Insomnia
About this trial
This is an interventional treatment trial for Chronic Insomnia focused on measuring chronic insomnia
Eligibility Criteria
Inclusion Criteria: Female patients aged 21-60 years old Have a negative serum or urine pregnancy test for women of child-bearing potential Have a three-month or longer history of insomnia Self-report < 6.5 hours of total sleep time, in addition to a sleep efficiency of less than 85%, averaged over two weeks of screening A score of less than 60 on the Zung Self-Rating Depression Scale Self-report bedtimes that do not vary by more than two hours on five nights per week Have completed chemotherapy for breast cancer less than two years prior to study drug administration Have completed chemotherapy for breast cancer for at least two months prior to screening visit Patients that are receiving Herceptin are eligible for study enrollment Have completed radiation therapy for breast cancer for at least two months prior to screening visit ECOG (Eastern Cooperative Oncology Group)score of 0-1 Be able to read, understand, and provide written informed consent before enrolling in the study Must be willing to comply with all study visits and comply with daily phone calls to the IVRS throughout the study Agree to participate for the entire study period (about two months) Exclusion Criteria: Metastatic disease Pregnant or lactating female Self-reports typical consumption of more than five alcoholic beverages on a single day or greater than 14 alcoholic beverages weekly Self-reports use of products containing nicotine of greater than 15 cigarettes daily or cannot avoid products containing nicotine during sleep periods Current use of any of the following medications, and cannot discontinue these medications for the duration of the study: Hypnotic medication, Anti-convulsants, Anxiolytics, Narcotic analgesics, Medications or supplements containing Melatonin, Ketaconazole and Fluconazole Currently taking fluvoxamine, brand name Luvox Have symptoms consistent with the diagnosis of any other sleep disorder other than insomnia (e.g. obstructive sleep apnea, narcolepsy, restless legs syndrome) Currently on night or rotating shift work Self-reports habitual napping of greater than one hour accumulated sleep on 4 or more days per week Has a psychiatric illness that interferes with normal sleep-wake function (e.g. major depression, post-traumatic stress disorder) A score of 60 or greater on the Zung Self-Rating Depression Scale Has current unstable medical disorder, such as symptomatic congestive heart failure, uncontrolled cardiac arrhythmia, or other serious medical condition as determined by the Investigator
Sites / Locations
- Genesis Cancer Center
- Wilshire Oncology Medical Group, Inc.
- Eastern Connecticut Hematology and Oncology Associates
- Augusta Oncology Associates, PC
- North Idaho Cancer Center
- Hematology Oncology Centers of the Northern Rockies
- Tri-County Hematology & Oncology Associates
- Pottsville Cancer Center
- The West Clinic
- Cancer Specialists of Tidewater, Ltd.
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Active Comparator
1 (Placebo)
2 (Ramelteon)
Patients will take placebo 30 minutes before bedtime days 1-28 of treatment period.
Patients will take 8 mgs of ramelteon 30 minutes before bedtime days 1-28 of treatment period.